{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:43:43Z","timestamp":1785869023358,"version":"3.56.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1014461","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000}}],"reference-count":86,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["-R01-AI-150246, 1-R01-AI-152362, 1-R01-AI-140539"],"award-info":[{"award-number":["-R01-AI-150246, 1-R01-AI-152362, 1-R01-AI-140539"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["Investigator"],"award-info":[{"award-number":["Investigator"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deans Innovation Fund"},{"name":"the Linda and Laddie Montague Foundation"},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5F31AI183630-02"],"award-info":[{"award-number":["5F31AI183630-02"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>\n                    Successful viruses including SARS-CoV-2 antagonize and evade immune detection to establish infection. As population immunity to the ancestral strain has risen, new variants\u2014particularly Omicron\u2014have evolved to avoid detection by both circulating antibodies and the innate immune system. Screening innate immune agonists, we previously identified STING agonists as potent inhibitors of the ancestral variant of SARS-CoV-2. When we explored the sensitivity of Omicron BA.1 to diverse innate stimuli, we found that Omicron is also sensitive to interferons and STING agonists; however, Omicron variants are uniquely restricted by small DNA oligonucleotide ligands known to activate TLR9. Mechanistic studies showed that short, but not long, DNA oligonucleotides of diverse sequences, including those that do not engage TLR9, block Omicron infection at an entry step downstream of TMPRSS2-mediated activation. Using genetic and pharmacological assays we confirmed that activity was independent of TLR9. Furthermore, these oligodeoxynucleotides (ODNs) are active\n                    <jats:italic>in vivo<\/jats:italic>\n                    , reducing SARS-CoV-2 Omicron titers. Together, these findings identify a previously unrecognized antiviral activity of short DNA oligonucleotides and establish them as selective inhibitors of SARS-CoV-2 Omicron entry.\n                  <\/jats:p>","DOI":"10.1371\/journal.ppat.1014461","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:47:17Z","timestamp":1785433637000},"page":"e1014461","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA oligonucleotides block viral entry of SARS-CoV-2 Omicron variants"],"prefix":"10.1371","volume":"22","author":[{"given":"Jorge A.","family":"Acu\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasirajan","family":"Ayyanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanupriya","family":"Whig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hewins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie Ann","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Frieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-6610","authenticated-orcid":true,"given":"Sara","family":"Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"3","key":"ppat.1014461.ref001","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"COVID-19 Genomics UK Consortium","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"ppat.1014461.ref002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"P Mlcochova","year":"2021","journal-title":"Nature"},{"issue":"9","key":"ppat.1014461.ref003","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"WF Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"7898","key":"ppat.1014461.ref004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"L Liu","year":"2022","journal-title":"Nature"},{"issue":"4","key":"ppat.1014461.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Q Wang","year":"2020","journal-title":"Cell"},{"issue":"2","key":"ppat.1014461.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"ppat.1014461.ref007","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.celrep.2021.108959","article-title":"Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2","volume":"35","author":"M Dittmar","year":"2021","journal-title":"Cell Rep"},{"issue":"16","key":"ppat.1014461.ref008","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021107821","article-title":"TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells","volume":"40","author":"J Koch","year":"2021","journal-title":"EMBO J"},{"issue":"2","key":"ppat.1014461.ref009","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"YJ Hou","year":"2020","journal-title":"Cell"},{"issue":"10","key":"ppat.1014461.ref010","doi-asserted-by":"crossref","DOI":"10.15252\/embj.20105114","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","volume":"39","author":"S Lukassen","year":"2020","journal-title":"EMBO J"},{"issue":"1","key":"ppat.1014461.ref011","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-022-28768-w","article-title":"Evolution of the SARS-CoV-2 spike protein in the human host","volume":"13","author":"AG Wrobel","year":"2022","journal-title":"Nat Commun"},{"key":"ppat.1014461.ref012","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.3390\/ijms222413397","article-title":"Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases","volume":"22","author":"K Wicherska-Paw\u0142owska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ppat.1014461.ref013","doi-asserted-by":"crossref","first-page":"1287940","DOI":"10.3389\/fimmu.2024.1287940","article-title":"Innate immune responses to RNA: sensing and signaling","volume":"15","author":"X Luan","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"ppat.1014461.ref014","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"R Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"ppat.1014461.ref015","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"EV Mesev","year":"2019","journal-title":"Nat Microbiol"},{"issue":"2","key":"ppat.1014461.ref016","doi-asserted-by":"crossref","first-page":"108628","DOI":"10.1016\/j.celrep.2020.108628","article-title":"MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells","volume":"34","author":"X Yin","year":"2021","journal-title":"Cell Rep"},{"key":"ppat.1014461.ref017","doi-asserted-by":"crossref","first-page":"700926","DOI":"10.3389\/fimmu.2021.700926","article-title":"RIG-I-like receptor-mediated recognition of viral genomic RNA of severe acute respiratory syndrome coronavirus-2 and viral escape from the host innate immune responses","volume":"12","author":"T Kouwaki","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"ppat.1014461.ref018","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","article-title":"Activation and evasion of type I interferon responses by SARS-CoV-2","volume":"11","author":"X Lei","year":"2020","journal-title":"Nat Commun"},{"issue":"59","key":"ppat.1014461.ref019","article-title":"Pharmacological activation of STING blocks SARS-CoV-2 infection","volume":"6","author":"M Li","year":"2021","journal-title":"Sci Immunol"},{"issue":"7897","key":"ppat.1014461.ref020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41586-021-04352-y","article-title":"Evolution of enhanced innate immune evasion by SARS-CoV-2","volume":"602","author":"LG Thorne","year":"2022","journal-title":"Nature"},{"issue":"2","key":"ppat.1014461.ref021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41564-023-01588-4","article-title":"Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants","volume":"9","author":"A-K Reuschl","year":"2024","journal-title":"Nat Microbiol"},{"issue":"5","key":"ppat.1014461.ref022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"T Kawai","year":"2010","journal-title":"Nat Immunol"},{"issue":"16","key":"ppat.1014461.ref023","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition","volume":"98","author":"S Bauer","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"ppat.1014461.ref024","doi-asserted-by":"crossref","first-page":"15124","DOI":"10.1074\/jbc.M313406200","article-title":"Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition","volume":"279","author":"S Corn\u00e9lie","year":"2004","journal-title":"J Biol Chem"},{"key":"ppat.1014461.ref025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of genetic variants among young men with severe COVID-19","volume":"324","author":"CI van der Made","year":"2020","journal-title":"JAMA"},{"key":"ppat.1014461.ref026","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67569","article-title":"Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study","volume":"10","author":"C Fallerini","year":"2021","journal-title":"Elife"},{"issue":"62","key":"ppat.1014461.ref027","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"T Asano","year":"2021","journal-title":"Sci Immunol"},{"issue":"2","key":"ppat.1014461.ref028","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/v14020189","article-title":"Induction of innate immune response by TLR3 agonist protects mice against SARS-CoV-2 infection","volume":"14","author":"H Tamir","year":"2022","journal-title":"Viruses"},{"key":"ppat.1014461.ref029","first-page":"51","article-title":"CpG oligonucleotides as vaccine adjuvants;","author":"N Kayraklioglu","year":"2021"},{"issue":"23","key":"ppat.1014461.ref030","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01250-22","article-title":"The P681H mutation in the spike glycoprotein of the alpha variant of SARS-CoV-2 escapes IFITM restriction and is necessary for type I interferon resistance","volume":"96","author":"MJ Lista","year":"2022","journal-title":"J Virol"},{"issue":"32","key":"ppat.1014461.ref031","article-title":"Interferon resistance of emerging SARS-CoV-2 variants","volume":"119","author":"K Guo","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ppat.1014461.ref032","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41392-020-00438-7","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I\/MDA-5 signaling","volume":"5","author":"Y Zheng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"ppat.1014461.ref033","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28680","article-title":"SARS-CoV-2 NSP8 suppresses type I and III IFN responses by modulating the RIG-I\/MDA5, TRIF, and STING signaling pathways","volume":"95","author":"J Deng","year":"2023","journal-title":"J Med Virol"},{"issue":"1","key":"ppat.1014461.ref034","doi-asserted-by":"crossref","first-page":"115115","DOI":"10.1016\/j.celrep.2024.115115","article-title":"Pressure to evade cell-autonomous innate sensing reveals interplay between mitophagy, IFN signaling, and SARS-CoV-2 evolution","volume":"44","author":"JS Lee","year":"2025","journal-title":"Cell Rep"},{"issue":"7736","key":"ppat.1014461.ref035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"JM Ramanjulu","year":"2018","journal-title":"Nature"},{"issue":"6506","key":"ppat.1014461.ref036","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"B-S Pan","year":"2020","journal-title":"Science"},{"issue":"6813","key":"ppat.1014461.ref037","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"H Hemmi","year":"2000","journal-title":"Nature"},{"issue":"5","key":"ppat.1014461.ref038","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","article-title":"Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA","volume":"157","author":"ZK Ballas","year":"1996","journal-title":"J Immunol"},{"issue":"34","key":"ppat.1014461.ref039","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1016\/j.vaccine.2011.05.087","article-title":"Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice","volume":"29","author":"Y Liu","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"ppat.1014461.ref040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"DM Klinman","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"ppat.1014461.ref041","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"AM Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ppat.1014461.ref042","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","article-title":"Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine","volume":"22","author":"CL Cooper","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"ppat.1014461.ref043","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/vaccines11030649","article-title":"CpG 1018 is an effective adjuvant for influenza nucleoprotein","volume":"11","author":"Y Li","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"24","key":"ppat.1014461.ref044","doi-asserted-by":"crossref","first-page":"126269","DOI":"10.1016\/j.vaccine.2024.126269","article-title":"A recombinant N2 neuraminidase-based CpG 1018\u00ae adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters","volume":"42","author":"I Hoxie","year":"2024","journal-title":"Vaccine"},{"issue":"19","key":"ppat.1014461.ref045","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"R Hyer","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"ppat.1014461.ref046","article-title":"Phase 1 trial of AMA1-C1\/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria","volume":"3","author":"GED Mullen","year":"2008","journal-title":"PLoS One"},{"issue":"52","key":"ppat.1014461.ref047","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1016\/j.vaccine.2009.10.087","article-title":"A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1\/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults","volume":"27","author":"I Sagara","year":"2009","journal-title":"Vaccine"},{"key":"ppat.1014461.ref048","doi-asserted-by":"crossref","first-page":"1267372","DOI":"10.3389\/fimmu.2023.1267372","article-title":"Safety and immunogenicity of BK-SE36\/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial","volume":"14","author":"A Ou\u00e9draogo","year":"2023","journal-title":"Front Immunol"},{"issue":"21","key":"ppat.1014461.ref049","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/Th1 responses and CD8 T cells through cross-priming","volume":"104","author":"D Valmori","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ppat.1014461.ref050","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1078-0432.CCR-10-1811","article-title":"Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients","volume":"17","author":"J Karbach","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"ppat.1014461.ref051","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"ZA Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"ppat.1014461.ref052","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"P Richmond","year":"2021","journal-title":"Lancet"},{"issue":"629","key":"ppat.1014461.ref053","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj5305","article-title":"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice","volume":"14","author":"E Nanishi","year":"2022","journal-title":"Sci Transl Med"},{"issue":"9","key":"ppat.1014461.ref054","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Z Dongye","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"ppat.1014461.ref055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2567.2005.02261.x","article-title":"Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha","volume":"117","author":"JD Marshall","year":"2006","journal-title":"Immunology"},{"issue":"1","key":"ppat.1014461.ref056","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"J Vollmer","year":"2004","journal-title":"Eur J Immunol"},{"issue":"7","key":"ppat.1014461.ref057","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"A Krug","year":"2001","journal-title":"Eur J Immunol"},{"issue":"4","key":"ppat.1014461.ref058","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.166.4.2372","article-title":"Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs","volume":"166","author":"D Verthelyi","year":"2001","journal-title":"J Immunol"},{"issue":"6522","key":"ppat.1014461.ref059","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"AM Krieg","year":"1995","journal-title":"Nature"},{"issue":"2","key":"ppat.1014461.ref060","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.164.2.944","article-title":"Mechanism and function of a newly identified CpG DNA motif in human primary B cells","volume":"164","author":"G Hartmann","year":"2000","journal-title":"J Immunol"},{"issue":"3","key":"ppat.1014461.ref061","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","article-title":"Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo","volume":"164","author":"G Hartmann","year":"2000","journal-title":"J Immunol"},{"issue":"5","key":"ppat.1014461.ref062","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1189\/jlb.71.5.813","article-title":"Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide","volume":"71","author":"M G\u00fcrsel","year":"2002","journal-title":"J Leukoc Biol"},{"issue":"9","key":"ppat.1014461.ref063","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2004-06-2468","article-title":"CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response","volume":"105","author":"GSD Reid","year":"2005","journal-title":"Blood"},{"issue":"3","key":"ppat.1014461.ref064","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.171.3.1393","article-title":"Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation","volume":"171","author":"I Gursel","year":"2003","journal-title":"J Immunol"},{"issue":"7904","key":"ppat.1014461.ref065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","author":"DC Schultz","year":"2022","journal-title":"Nature"},{"issue":"2","key":"ppat.1014461.ref066","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1097-2765(00)80136-7","article-title":"MyD88 is an adaptor protein in the hToll\/IL-1 receptor family signaling pathways","volume":"2","author":"R Medzhitov","year":"1998","journal-title":"Mol Cell"},{"issue":"6599","key":"ppat.1014461.ref067","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/383443a0","article-title":"TRAF6 is a signal transducer for interleukin-1","volume":"383","author":"Z Cao","year":"1996","journal-title":"Nature"},{"issue":"9","key":"ppat.1014461.ref068","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa","volume":"28","author":"H Tegally","year":"2022","journal-title":"Nat Med"},{"issue":"7902","key":"ppat.1014461.ref069","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"R Viana","year":"2022","journal-title":"Nature"},{"issue":"9","key":"ppat.1014461.ref070","doi-asserted-by":"crossref","first-page":"110428","DOI":"10.1016\/j.celrep.2022.110428","article-title":"Cryo-EM structure of the SARS-CoV-2 Omicron spike","volume":"38","author":"G Cerutti","year":"2022","journal-title":"Cell Rep"},{"issue":"37","key":"ppat.1014461.ref071","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204717119","article-title":"SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis","volume":"119","author":"ME McGrath","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ppat.1014461.ref072","article-title":"Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2","volume":"28","author":"JB Case","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"7961","key":"ppat.1014461.ref073","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-023-06025-4","article-title":"SARS-CoV-2 Omicron boosting induces de novo B cell response in humans","volume":"617","author":"WB Alsoussi","year":"2023","journal-title":"Nature"},{"issue":"8","key":"ppat.1014461.ref074","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41588-022-01110-2","article-title":"Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs","volume":"54","author":"A Rebendenne","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"ppat.1014461.ref075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1465-9921-6-25","article-title":"Local therapy with CpG motifs in a murine model of allergic airway inflammation in IFN-beta knock-out mice","volume":"6","author":"V Matheu","year":"2005","journal-title":"Respir Res"},{"issue":"2","key":"ppat.1014461.ref076","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mi.2014.62","article-title":"Matrix protein CCN1 induced by bacterial DNA and CpG ODN limits lung inflammation and contributes to innate immune homeostasis","volume":"8","author":"H-G Moon","year":"2015","journal-title":"Mucosal Immunol"},{"key":"ppat.1014461.ref077","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1158\/0008-5472.CAN-08-2779","article-title":"Immune rejection of mouse tumors expressing mutated self","volume":"69","author":"F Duan","year":"2009","journal-title":"Cancer Res"},{"key":"ppat.1014461.ref078","article-title":"A novel C type CpG oligodeoxynucleotide exhibits immunostimulatory activity in vitro and enhances antitumor effect in vivo","volume":"11","author":"T Li","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"ppat.1014461.ref079","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","article-title":"Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor","volume":"11","author":"J Yang","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"ppat.1014461.ref080","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Y Cao","year":"2020","journal-title":"Cell"},{"issue":"7909","key":"ppat.1014461.ref081","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","article-title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic","volume":"605","author":"T Shapira","year":"2022","journal-title":"Nature"},{"issue":"1","key":"ppat.1014461.ref082","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1038\/s41467-025-60832-z","article-title":"An orally available Mpro\/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo","volume":"16","author":"H Shuai","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"ppat.1014461.ref083","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4049\/jimmunol.173.2.1179","article-title":"TLR9 is localized in the endoplasmic reticulum prior to stimulation","volume":"173","author":"CA Leifer","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"ppat.1014461.ref084","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/icb.2008.101","article-title":"TLR9 traffics through the Golgi complex to localize to endolysosomes and respond to CpG DNA","volume":"87","author":"A Chockalingam","year":"2009","journal-title":"Immunol Cell Biol"},{"issue":"9","key":"ppat.1014461.ref085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073894","article-title":"PIKfyve regulates the endosomal localization of CpG oligodeoxynucleotides to elicit TLR9-dependent cellular responses","volume":"8","author":"K Hazeki","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"ppat.1014461.ref086","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.0802442","article-title":"The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes","volume":"184","author":"SD de Jong","year":"2010","journal-title":"J Immunol"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1014461","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:44:30Z","timestamp":1785865470000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014461"}},"subtitle":[],"editor":[{"given":"Roberto","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":86,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1014461","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}